How should we introduce clinical PET in UK? The oncologists need to have a view

Clinical Oncology

Volumn 16, Issue 3, 2004, Pages 172-175

  Price, Pat ^a   Laking, G ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

CANCER STAGING; CYCLOTRON; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DRUG HALF LIFE; EDITORIAL; EUROPE; FRANCE; GERMANY; HEALTH CARE COST; HEALTH CARE ORGANIZATION; MEDICAL SPECIALIST; MEDICAL TECHNOLOGY; NATIONAL HEALTH SERVICE; NUCLEAR MEDICINE; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM; UNITED STATES;

EID: 2342442643     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2004.02.004     Document Type: Editorial

References (9)

1. Jerusalem G, Hustinx R, Beguin Y, et al. PET scan imaging in oncology. Eur J Cancer 2003;39:1525-1534.
2. Bradbury I, Boynton J, Cummins E, et al. Positron emission tomography (PET) imaging in cancer management. Health Technology Assessment Report 2. Glasgow: Health Technology Board for Scotland, 2002.
3. Bradbury I, Facey K, Laking G, et al. Investing in new technology: the PET experience. Br J Cancer 2003;89:224-227.
4. Thornbury JR, Fryback DG. Technology assessment - an American view. Eur J Radiol 1992;14:147-156.
5. Boyer M, Viney R, Fulham MA. Randomised trial of conventional staging with or without positron emission tomography in patients with stage 1 or 2 non-small cell lung cancer. Proceedings of the American Society of Clinical Oncology 20 [abstract 1233], 2001.
6. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388-1393.
7. Claxton K, Sculpher M, Drummond A. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 2002;360:711-715.
8. Dietlein M, Schicha H. Reimbursement of the PET in oncology in Europe: a questionnaire based survey [in German]. Nuklearmedizin 2003;42:80-85.
9. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35:1773-1782.